Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Net Margin (2022 - 2025)

Stoke Therapeutics has reported Net Margin over the past 4 years, most recently at 4124.39% for Q4 2025.

  • Quarterly results put Net Margin at 4124.39% for Q4 2025, down 407715.0% from a year ago — trailing twelve months through Dec 2025 was 3.67% (up 24029.0% YoY), and the annual figure for FY2025 was 3.71%, up 23904.0%.
  • Net Margin for Q4 2025 was 4124.39% at Stoke Therapeutics, down from 360.68% in the prior quarter.
  • Over the last five years, Net Margin for STOK hit a ceiling of 71.19% in Q1 2025 and a floor of 4124.39% in Q4 2025.
  • Median Net Margin over the past 4 years was 684.35% (2023), compared with a mean of 811.55%.
  • Biggest five-year swings in Net Margin: skyrocketed 91632bps in 2024 and later tumbled -407715bps in 2025.
  • Stoke Therapeutics' Net Margin stood at 786.32% in 2022, then decreased by -23bps to 963.56% in 2023, then soared by 95bps to 47.24% in 2024, then plummeted by -8631bps to 4124.39% in 2025.
  • The last three reported values for Net Margin were 4124.39% (Q4 2025), 360.68% (Q3 2025), and 169.96% (Q2 2025) per Business Quant data.